Trial reportInternational journal of immunopathology and pharmacology2016
Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.
Trial report in International journal of immunopathology and pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02690103 (Clinical Study of a Biological Response Modifier), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of a Biological Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for the Treatment of Hepatitis C Infection
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Basophilic Response in Patients with Persistent Symptoms Attributed to Lyme Borreliosis Treated with Hydrolysed Arabinoxylan Rice Bran.Medicina (Kaunas, Lithuania) · 2025Trial
- Trial
- Rice Bran Arabinoxylan Compound and Tryptophan Metabolism on Quality of Life of Cancer Patients: A Secondary Analysis of the RBAC-QoL Study.International journal of tryptophan research : IJTR · 2026Article
- Article
- Biobran/MGN-3, an Arabinoxylan Rice Bran, Exerts Anti-COVID-19 Effects and Boosts Immunity in Human Subjects.Nutrients · 2024Article
- Biobran-loaded core/shell nanofibrous scaffold: a promising wound dressing candidate.RSC advances · 2024Article
- Article
- Modified rice bran arabinoxylan as a nutraceutical in health and disease-A scoping review with bibliometric analysis.PloS one · 2023Article
- The Health-Promoting Properties and Clinical Applications of Rice Bran Arabinoxylan Modified with Shiitake Mushroom Enzyme-A Narrative Review.Molecules (Basel, Switzerland) · 2021Review
- Rice Bran By-Product: From Valorization Strategies to Nutritional Perspectives.Foods (Basel, Switzerland) · 2021Review
- Protective Effect of Biobran/MGN-3 against Sporadic Alzheimer's Disease Mouse Model: Possible Role of Oxidative Stress and Apoptotic Pathways.Oxidative medicine and cellular longevity · 2021Article
- Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial.Experimental and therapeutic medicine · 2018Article
- Biobran/MGN-3, Arabinoxylan Rice Bran, Ameliorates the Liver Architecture in Ehrlich Ascites Tumor-Bearing Mice as a Cotreatment with Chemotherapy.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Current treatments for Hepatitis C virus (HCV) have severe side effects and are very expensive. There is a need to explore effective natural therapies against HCV that are less toxic and more cost-effective. In the current study, 37 chronic HCV patients were randomized into two groups and treated with either pegylated interferon (PEG IFN) plus ribavirin (n = 21) or Biobran, an arabinoxylan from rice bran (1 g/day) (n = 16). We examined viremia, liver enzymes, interferon-γ (IFN-γ) levels in serum, and toxicity before and three months after treatment. Both groups showed a significant and similar reduction in viral load after three months of treatment relative to the baseline viral load (P <0.05). In addition, treatment with Biobran resulted in a significant increase in the level of IFN-γ (P <0.001). Patients in the PEG IFN plus ribavirin group showed fever, anemia, thrombocytopenia, and easy fatigue. Patients in the Biobran group showed no side effects and reported good health. We conclude that Biobran is a potential novel therapeutic regimen that has a similar effect to PEG IFN plus ribavirin and is safe and cost-effective in the treatment of chronic HCV. Our finding of Biobran's efficacy against HCV infection warrants further investigation in multiple clinical trials (Clinical Trials Registration: NCT02690103).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.